Neurology
-
Randomized Controlled Trial
Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial.
To determine whether the tumor necrosis factor α inhibitor etanercept is well tolerated and obtain preliminary data on its safety in Alzheimer disease dementia. ⋯ This study shows Class I evidence that weekly subcutaneous etanercept is well tolerated in Alzheimer disease dementia.
-
To examine the pricing trajectories in the United States of disease-modifying therapies (DMT) for multiple sclerosis (MS) over the last 20 years and assess the influences on rising prices. ⋯ MS DMT costs have accelerated at rates well beyond inflation and substantially above rates observed for drugs in a similar biologic class. There is an urgent need for clinicians, payers, and manufacturers in the United States to confront the soaring costs of DMTs.